Kazufumi Nakamura is an Investment Director focused on biotech and life science areas. He thinks the most powerful thing about being a part of this industry is having the opportunity to improve the lives of patients and their families. While always appreciative of entrepreneurs’ willingness to take bold new approaches to treat severe disease, he is especially excited by initiatives by start-ups focusing on areas where genetics and genomics bring new insight into disease biology. By leveraging his experiences and networks in Pharma, Biotech and Academia, he connects companies to those experts to expand business and gain scientific insight to help our companies succeed with their important missions.
Kazufumi has over 15 years of healthcare and life sciences experience, spanning business development, investment, entrepreneurship and R&D. Prior to joining MGI, he co-founded a biotech to accelerate innovations through academic institutions in Japan. Previously, he engaged in business development and conducted scientific evaluation, and license-in and license-out of pharmaceutical products at Santen Pharmaceuticals. In addition, he was responsible for creating relationships with the leading academic institutions and innovators, gaining Santen early access to innovation. Prior to Santen, he held a number of clinical development roles at Janssen Pharmaceuticals, including the development of Alzheimer’s disease and Rheumatoid arthritis programs. He holds a B.S. in pharmaceutical science from Tokyo University of Science and is a Pharmacist (Japan).
In his spare time, he enjoys running after his son, driving across the countryside and exploring tasty craft sake.